Stock CING CINGULATE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cingulate Inc.

Equities

CING

US17248W2044

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
0.586 USD -3.46% Intraday chart for Cingulate Inc. +2.81% -92.34%
05-21 FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD CI
05-08 Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 31.21 11.31 7.168 4.049 - -
Enterprise Value (EV) 1 31.21 11.31 7.168 4.049 4.049 4.049
P/E ratio -0.99 x -0.64 x -0.29 x -0.28 x -0.25 x 0.65 x
Yield - - - - - -
Capitalization / Revenue - - - - - 0.22 x
EV / Revenue - - - - - 0.22 x
EV / EBITDA - - - - - -
EV / FCF - -705,241 x - - - -
FCF Yield - -0% - - - -
Price to Book - 2.91 x -1.3 x -0.98 x -0.2 x -
Nbr of stocks (in thousands) 565 565 937 6,910 - -
Reference price 2 55.20 20.00 7.650 0.5860 0.5860 0.5860
Announcement Date 22-03-10 23-03-10 24-04-01 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 18.83
EBITDA - - - - - - -
EBIT 1 - -20.68 -17.5 -22.76 -10.46 -13.62 4.537
Operating Margin - - - - - - 24.09%
Earnings before Tax (EBT) 1 - -20.71 -17.68 -23.53 -10.52 -13.62 4.537
Net income 1 -7.184 -20.71 -17.68 -23.53 -10.52 -13.62 4.537
Net margin - - - - - - 24.09%
EPS 2 - -55.80 -31.20 -26.00 -2.060 -2.335 0.9000
Free Cash Flow - - -16.04 - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 21-05-24 22-03-10 23-03-10 24-04-01 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -2.647 -5.009 -4.049 -3.968 -4.475 -3.85 -6.362 -5.75 -6.797 -2.948 -2.576 -2.51 -2.448 -4 -4
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -2.654 -5.004 -4.04 -4.027 -4.605 -4.005 -6.616 -5.979 -6.935 -2.972 -2.576 -2.51 -2.448 -4 -4
Net income 1 -2.654 -5.004 -4.04 -4.027 -4.605 -4.005 -6.616 -5.979 -6.935 -2.972 -2.576 -2.51 -2.448 -4 -4
Net margin - - - - - - - - - - - - - - -
EPS 2 -23.40 -8.800 -7.200 -7.200 -8.000 -7.000 -11.40 -6.000 -1.600 -0.6000 -0.4700 -0.4500 -0.4400 -0.6300 -0.6200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 22-03-10 22-05-12 22-08-11 22-11-14 23-03-10 23-05-10 23-08-14 23-11-13 24-04-01 24-05-08 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - -16 - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - - 6.870 -5.880 -0.6000 -2.860 -
Cash Flow per Share - - - - - - -
Capex 1 - 0.81 0.15 0.22 0.5 0.5 -
Capex / Sales - - - - - - -
Announcement Date 21-05-24 22-03-10 23-03-10 24-04-01 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.586 USD
Average target price
14 USD
Spread / Average Target
+2,289.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CINGULATE INC. Stock Cingulate Inc.
-92.34% 4.05M
MODERNA, INC. Stock Moderna, Inc.
+38.36% 52.73B
LONZA GROUP AG Stock Lonza Group AG
+38.76% 39B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.63% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.46% 30.38B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.39B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.44% 26.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.09% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.93% 12.6B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.30% 11.51B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CING Stock
  4. Financials Cingulate Inc.